share_log

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $18 Price Target

Benzinga ·  Dec 5, 2023 06:28

HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $18 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment